EFFICACY OF KANTAKARI AVALEHA AND KANTAKARI GRANULES IN TAMAKA SHWASA.

PHARMACEUTICAL STANDARDIZATION AND SHELF LIFE STUDY OF KANTAKARI AVALEHA AND ITS GRANULES AND THEIR EFFECT ON TAMAKA SHWASA (BRONCHIAL ASTHMA) - PROSPECTIVE

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018465

Enrollment

Registered

2019-04-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: KANTAKARI AVALEHA GRANULES: 6 GM BD FOR 2 MONTHS Control Intervention1: KANTAKARI AVALEHA: 6 GM BD FOR 2 MONTHS

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with classical signs and symptoms of Tamaka Shwasa

Exclusion criteria

Exclusion criteria: Known patients of diabetes and uncontrolled systemic arterial hypertension.Dyspnoea resulting from cardiac origin, severe anemia with Hb%6.Age above 60 years and below 18 years,

Design outcomes

Primary

Measure	Time frame
IT IS EXPECTED THAT TRIAL DRUG WILL EXTRA A SIGNIFICANT ON SIGNS AND SYMPTOMS OF TAMAKA SHWASATimepoint: 14 months	—

Secondary

Measure	Time frame
IMPROVMENT IN GENERAL HEALTH CONDITION OF PATIENTSTimepoint: AFTER 1 MONTH OF TREATMENT	—

Countries

India

Contacts

Public ContactUndiyaralalage Sampath Ruwan Kumari Senarathne

IPGT AND RA Jamnagar

patgiri124@gmail.com9426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026